All In Biotech

Drugs by condition

Drugs approved for wet macular degeneration

Brand-name prescription drugs and biologics whose FDA label lists wet macular degeneration as an approved use. Matched on the label phrases: "neovascular (wet) age-related macular degeneration", "macular degeneration".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

18

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

7

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for wet macular degeneration.

  • Lucamzi (Ranibizumab-Blrz) · Xbrane Biopharma Ab Oct 27, 2026
  • Pavblu (Aflibercept-Ayyh) · Amgen INC Oct 22, 2026
  • Enzeevu (Aflibercept-Abzv) · Sandoz INC Oct 22, 2026
  • Lytenava (Bevacizumab-Vikg) · Outlook Therapeutics, Inc. NovelJul 24, 2026
  • Nufymco (Ranibizumab-Leyk) · Formycon AG Dec 18, 2025

All approved drugs for wet macular degeneration, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Vascular Endothelial Growth Factor Inhibitor (11)

  • Lytenava Bevacizumab-Vikg · Outlook Therapeutics, Inc. · 2026
  • Eylea Aflibercept · Regeneron Pharmaceuticals · 2011
  • Lucentis Ranibizumab · Genentech · 2006
  • Pavblu Aflibercept-Ayyh · Amgen INC · 2026
  • Enzeevu Aflibercept-Abzv · Sandoz INC · 2026
  • Nufymco Ranibizumab-Leyk · Formycon AG · 2025
  • Yesafili Aflibercept-Jbvf · Biocon Biologics INC · 2024
  • Eylea Hd Aflibercept · Regeneron Pharmaceuticals · 2023
  • Cimerli Ranibizumab-Eqrn · Sandoz INC · 2022
  • Susvimo Ranibizumab · Genentech INC · 2021
  • Byooviz Ranibizumab-Nuna · Samsung Bioepis CO LTD · 2021

Photoenhancer (1)

  • Visudyne Verteporfin · Bausch Lomb Ireland · 2000

Complement Inhibitor (1)

  • Syfovre Pegcetacoplan · Apellis Pharms · 2023

Class not listed in FDA's data (5)

  • Izervay Avacincaptad Pegol Sodium · Astellas · 2023
  • Vabysmo Faricimab-Svoa · Genentech INC · 2022
  • Beovu Brolucizumab-Dbll · Novartis Pharms Corp · 2019
  • Lucamzi Ranibizumab-Blrz · Xbrane Biopharma Ab · 2026
  • Ahzantive Aflibercept-Mrbb · Formycon AG · 2024

Drugs in development for wet macular degeneration

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • siRNAADX-038, ADX-324Phase 37 trials

    ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1

  • 4D-1503E10 vg, eyePhase 35 trials

    4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration

  • CemdisiranALN-CC5Phase 35 trials

    Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)

  • TiespectusEYE201, MK-8748Phase 35 trials

    EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization

  • EYP-1901Phase 34 trials

    EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)

  • OLN324Phase 34 trials

    Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration

  • PRL3-ZUMABPhase 34 trials

    Intra-IMMUSG Pte Ltd · Advanced Malignant Solid Tumor, Solid Tumor, Advanced Solid Cancers

  • ALK-001C20-D3-Retinyl Acetate, C20 Deuterated vitamin APhase 33 trials

    Alkeus Pharmaceuticals, Inc. · Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy

  • OTX-TKIaxitinib implantPhase 33 trials

    Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)

  • RemigromigEYE103, RestoretPhase 33 trials

    EyeBiotech Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)

  • BAT5906Phase 32 trials

    Bio-Thera Solutions · Diabetic Macular Edema (DME), Neovascular (Wet) Age-related Macular Degeneration

  • IBI302Phase 32 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Neovascular Age-related Macular Degeneration, Diabetic Macular Oedema

  • JNJ-81201887AAVCAGsCD59Phase 32 trials

    Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration

  • Surabgene LomparvovecABBV-RGX-314Phase 32 trials

    AbbVie · Diabetic Retinopathy, Neovascular Age-related Macular Degeneration

  • Tabirafusp tedromerKSI-501Phase 32 trials

    Kodiak Sciences Inc · Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration

  • TarcocimabTarcocimab tedromer, KSI-301Phase 32 trials

    Kodiak Sciences Inc · Wet Age-related Macular Degeneration, Diabetic Retinopathy

  • ABP 938Phase 31 trial

    Amgen · Neovascular Age-related Macular Degeneration, nAMD

  • HLX04-OPhase 31 trial

    Shanghai Henlius Biotech · Age Related Macular Degeneration

  • OCU410Phase 31 trial

    Ocugen · Dry Age-related Macular Degeneration

  • QL1207HPhase 31 trial

    Qilu Pharmaceutical Co., Ltd. · Neovascular Age-Related Macular Degeneration (nAMD)

More on wet macular degeneration: recruiting trials · published research

Related in ophthalmology: Diabetic macular edema · Glaucoma · Dry eye disease · Geographic atrophy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.